Antineoplastic activity of taxol against human anaplastic thyroid carcinoma cell lines in vitro and in vivo

Journal of Clinical Endocrinology and Metabolism

Volumn 81, Issue 10, 1996, Pages 3650-3653

  Ain, Kenneth B ^a   Tofiq, Sharmen ^b   Taylor, Kimberly D ^b  

^a UNIVERSITY OF KENTUCKY MEDICAL CENTER   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

PACLITAXEL;

ANAPLASTIC CARCINOMA; ANIMAL EXPERIMENT; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER GROWTH; CANCER INHIBITION; CANCER TRANSPLANTATION; CARCINOMA CELL; CELL COUNT; CONTROLLED STUDY; DOSE RESPONSE; HUMAN; HUMAN CELL; MONOLAYER CULTURE; MOUSE; NONHUMAN; NUDE MOUSE; PRIORITY JOURNAL; SUBCUTANEOUS DRUG ADMINISTRATION; THYROID CARCINOMA;

ANIMALS; CARCINOMA; CELL COUNT; CELL DIVISION; DOSE-RESPONSE RELATIONSHIP, DRUG; HUMANS; MICE; MICE, NUDE; NEOPLASM TRANSPLANTATION; PACLITAXEL; THYROID NEOPLASMS; TUMOR CELLS, CULTURED;

ANIMALIA; MUS MUSCULUS;

EID: 0029823530     PISSN: 0021972X     EISSN: None     Source Type: Journal    
DOI: 10.1210/jc.81.10.3650     Document Type: Article

References (19)

1. Carcangiu ML, Steeper T, Zampi G, Rosai J. 1985 Anaplastic thyroid carcinoma: a study of 70 cases. Am J Clin Pathol. 83:135-158.
2. Kohler DR, Goldspiel BR. 1994 Paclitaxel (taxol). Pharmacotherapy. 14:3-34.
3. Pályi I, Péter I, Daubner D, Vincze B, Lr̈incz I. 1993 Establishment, characterization and drug sensitivity of a new anaplastic thyroid carcinoma cell line (BHT-101). Virchows Arch B Cell Pathol. 63:263-269.
4. Attia MA, Weiss DW. 1966 Immunology of spontaneous mammary carcinomas in mice. V. Acquired tumor resistance and enhancement of strain-A mice injected with mammary tumor virus. Cancer Res. 26:1787-1800.
5. Riondel J, Jacrot M, Picot F, Beriel H, Mouriquand C, Potier P. 1986 Therapeutic response to taxol of six human tumours xenografted into nude mice. Cancer Chemother Pharmacol. 17:137-142.
6. Dunnett CW. 1955 A multiple comparison procedure for comparing several treatments with a control. J Am Stat Assoc. 50:1096-1121.
7. Dunnett CW. 1964 New tables for multiple comparisons with a control. Biometrics. 20:482-491.
8. Berger DP, Winterhalter BR, Fiebig HH. 1991 Conventional chemotherapy. In: Boven E, Winograd B, ed. The nude mouse in oncology research. Boca Raton: CRC Press; 165-184.
9. Mattern J, Bak M, Hahn EW, Volm M. 1988 Human tumor xenografts as model for drug testing. Cancer Metastasis Rev. 7:263-284.
10. Huizing MT, Sewberath Misser VHS, Pieters RC, et al. 1995 Taxanes: a new class of antitumor agents. Cancer Invest. 13:381-404.
11. 1-acid glycoprotein. Res Commun Chem Pathol Pharmocol. 80:337-344.
12. 1 phase by interference with spindle formation without affecting other microtubule functions during anaphase and telephase. Cancer Res. 54:4355-4361.
13. Liebmann JE, Cook JA, Lipschultz C, Teague D, Fisher J, Mitchell JB. 1993 Cytotoxic studies of paclitaxel (Taxol®) in human tumour cell lines. Br J Cancer. 68:1104-1109.
14. Matsuoka H, Furusawa M, Tomoda H, Seo Y. 1994 Difference in cytotoxicity of paclitaxel against neoplastic and normal cells. Anticancer Res. 14:163-168.
15. Rose WC. 1992 Taxol: a review of its preclinical in vivo antitumor activity. Anti-Cancer Drugs. 3:311-321.
16. 1 mice. Cancer Chemother Pharmacol. 34:465-471.
17. Silvestrini R, Zaffaroni N, Orlandi L, Oriana S. 1993 In vitro cytotoxic activity of taxol® and taxotere on primary cultures and established cell lines of human ovarian cancer. Stem Cells. 11:528-535.
18. Vogel M, Hilsenbeck SG, Depenbrock H, et al. 1993 Preclinical activity of taxotere (RP 56976, NSC 628503) against freshly explanted clonogenic human tumour cells: comparison with taxol and conventional antineoplastic agents. Eur J Cancer. 29A:2009-2014.
19. Fiebig HH, Berger DP. 1991 Preclinical phase II trials. In: Boven E, Winograd B, ed. The nude mouse in oncology research. Boca Raton: CRC Press; 317-326.